Background: Adhesion molecules play important roles in the pathophysiology of ischemic stroke. The aim of the present study was to investigate whether serum levels of soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cellular adhesion molecule 1 (sVCAM-1) and soluble E-selectin were associated with neurological deterioration of ischemic stroke. Methods: 238 consecutive patients with ischemic stroke examined within 24 h from onset were enrolled into the study. The stroke severity was daily assessed with the NIH Stroke Scale (NIHSS) within the first week after admission. Serum levels of sICAM-1, sVCAM-1 and sE-selectin after admission were measured using enzyme-linked immunosorbent assay. Multivariate logistic regression was used to analyze the association of serum levels of sICAM-1, sVCAM-1 and sE-selectin on admission with the neurological deterioration of ischemic stroke, adjusted for potential confounders. Results: 52 (21.8%) out of 238 stroke patients suffered from neurological deterioration. Serum levels of sICAM-1 on admission of stroke patients were significantly higher than those of healthy controls. Compared with patients without deterioration, patients with neurological deterioration had higher levels of sICAM-1, but not of sVCAM-1 and sE-selectin. On multivariate logistic regression, the serum level of sICAM-1 on admission was associated with neurological deterioration of stroke (OR 2.92, 95% CI 1.41–6.05). Other variables associated with neurological deterioration were fasting serum glucose (OR 1.65, 95% CI 1.24–2.20), baseline fibrinogen (OR 1.31, 95% CI 1.13–1.52) and NIHSS score (OR 1.23, 95% CI 1.15–1.32). Conclusions: The serum level of sICAM-1 on admission is associated with neurological deterioration of ischemic stroke.

Keywords:
Soluble intercellular adhesion molecule 1, Ischemic stroke, deterioration
1.
Toni D, Fiorelli M, Gentile M, Bastianello S, Sacchetti ML, Argentino C, Pozzilli C, Fieschi C: Progressing neurological deficit secondary to acute ischemic stroke: a study on predictability, pathogenesis, and prognosis. Arch Neurol 1995;52:670–675.
2.
Davalos A, Cendra E, Teruel J, Martinez M, Genis D: Deteriorating ischemic stroke: risk factors and prognosis. Neurology 1990;40:1865–1869.
3.
Castillo J, Rodriguez I: Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004;17(suppl 1):7–18.
4.
Castillo J, Leira R: Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms. Would its early treatment be useful? Cerebrovasc Dis 2001;11(suppl 1):40–48.
5.
Castillo J: Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment. Cerebrovasc Dis 1999;9(suppl 3):1–8.
6.
Fassbender K, Bertsch T, Mielke O, Muhlhauser F, Hennerici M: Adhesion molecules in cerebrovascular diseases: evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke 1999;30:1647–1650.
7.
Selakovic V, Colic M, Jovanovic M, Raicevic R, Jovicic A: Cerebrospinal fluid and plasma concentration of soluble intercellular adhesion molecule 1, vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule in patients with acute ischemic brain disease. Vojnosanit Pregl 2003;60:139–146.
8.
Fassbender K, Mossner R, Motsch L, Kischka U, Grau A, Hennerici M: Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke 1995;26:1361–1364.
9.
Clark WM, Zivin JA: Antileukocyte adhesion therapy: preclinical trials and combination therapy. Neurology 1997;49:S32–38.
10.
Zhou DH, Wang JY, Li J, Deng J, Gao C, Chen M: Study on frequency and predictors of dementia after ischemic stroke: the Chongqing stroke study. J Neurol 2004;251:421–427.
11.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST – Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
12.
Zhou H, Deng J, Li J, Wang Y, Zhang M, He H: Study of the relationship between cigarette smoking, alcohol drinking and cognitive impairment among elderly people in China. Age Ageing 2003;32:205–210.
13.
Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Maiwald M, Rohlfs M, Suhr H, Fiehn W, Becher H, Hacke W: Recent infection as a risk factor for cerebrovascular ischemia. Stroke 1995;26:373–379.
14.
Chamorro A, Cervera A, Castillo J, Davalos A, Aponte JJ, Planas AM: Unfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patients. Neurosci Lett 2002;328:229–232.
15.
Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000;31:2325–2329.
16.
Davalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J: Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke 1999;30:2631–2636.
17.
Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS: Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344:156–159.
18.
Davalos A, Castillo J, Pumar JM, Noya M: Body temperature and fibrinogen are related to early neurological deterioration in acute ischemic stroke. Cerebrovasc Dis 1997;7:64–69.
19.
Frijns CJ, Kappelle LJ: Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002;33:2115–2122.
20.
Frijns CJ, Kappelle LJ, van Gijn J, Nieuwenhuis HK, Sixma JJ, Fijnheer R: Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke 1997;28:2214–2218.
21.
Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P: A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998;29:2129–2135.
22.
Shyu KG, Chang H, Lin CC: Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke. J Neurol 1997;244:90–93.
23.
Clark WM, Coull BM, Briley DP, Mainolfi E, Rothlein R: Circulating intercellular adhesion molecule-1 levels and neutrophil adhesion in stroke. J Neuroimmunol 1993;44:123–125.
24.
Mori E, del Zoppo GJ, Chambers JD, Copeland BR, Arfors KE: Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke 1992;23:712–718.
25.
Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, del Zoppo GJ: P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994;25:202–211.
26.
del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM: Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991;22:1276–1283.
27.
Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N, Pinsky DJ, Stern DM: Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000;6:1355–1361.
28.
Akman HO, Zhang H, Siddiqui MA, Solomon W, Smith EL, Batuman OA: Response to hypoxia involves transforming growth factor-beta2 and Smad proteins in human endothelial cells. Blood 2001;98:3324–3331.
29.
Clark WM: Cytokines and reperfusion injury. Neurology 1997;49:S10–14.
30.
Ishikawa M, Cooper D, Russell J, Salter JW, Zhang JH, Nanda A, Granger DN: Molecular determinants of the prothrombogenic and inflammatory phenotype assumed by the postischemic cerebral microcirculation. Stroke 2003;34:1777–1782.
31.
Pierangeli SS, Espinola RG, Liu X, Harris EN: Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001;88:245–250.
32.
Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE: Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000;283:2395–2403.
33.
Chen J, Ma Y, Liang H: Effect of different injections of Chinese herbal medicine on stress hormones and immune cell factors in patients of type 2 diabetes mellitus complicated with acute cerebral infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000;20:815–817.
34.
Guan X, Wu W, Kuang P, Kuang P, Gao Y, Guan L, Li L, Mao X, Liu M: Metabolic changes in rats with photochemically induced cerebral infarction and the effects of batroxobin: a study by magnetic resonance imaging, 1H- and 31P-magnetic resonance spectroscopy. J Tradit Chin Med 2001;21:59–67.
35.
Lin S, Lian Q, Liang H: Clinical study on active factors of vascular endothelial cells in acute cerebral infarction patients and therapeutical effect of activating blood stasis. Zhongguo Zhong Xi Yi Jie He Za Zhi 1998;18:392–395.
36.
Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA: Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003;34:2543–2548.
37.
Enlimomab Acute Stroke Trial Investigators: Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001;57:1428–1434.
38.
Becker KJ: Anti-leukocyte antibodies: Leukarrest (Hu23F2G) and enlimomab (R6.5) in acute stroke. Curr Med Res Opin 2002;18(suppl 2):s18–22.
39.
Price CJ, Warburton EA, Menon DK: Human cellular inflammation in the pathology of acute cerebral ischaemia. J Neurol Neurosurg Psychiatry 2003;74:1476–1484.
40.
Furuya K, Takeda H, Azhar S, McCarron RM, Chen Y, Ruetzler CA, Wolcott KM, De Graba TJ, Rothlein R, Hugli TE, del Zoppo GJ, Hallenbeck JM: Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke 2001;32:2665–2674.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.